[Management View]
Co-Diagnostics reported a significant revenue decline in Q2 2025, primarily due to the absence of grant income. The company is advancing clinical evaluations for its Kodiak PCR platform, with trials for COVID-19, multiplex flu A/B/COVID-19/RSV, tuberculosis, and HPV tests expected to begin in 2025. Management emphasized operational efficiency and cost control while preparing for FDA submissions and international launches.

[Outlook]
The company plans to initiate clinical evaluations for all tests in its pipeline during 2025, with a focus on U.S. and Indian markets. FDA clearance for the COVID-19 test is anticipated by mid-2026. Commercialization efforts will target physician offices, clinics, nursing facilities, home use, and pharmacies in the U.S., and primary health care centers in India.

[Financial Performance]
- Total Revenue: $200,000 in Q2 2025, down from $2,700,000 in Q2 2024.
- Total Operating Expenses: $8,200,000, down from $10,100,000 in Q2 2024.
- Research and Development Expenses: $4,700,000, down from $5,600,000 in Q2 2024.
- Net Loss: $7,700,000 or $0.23 per share, compared to $7,600,000 or $0.25 per share in Q2 2024.
- Adjusted EBITDA: Loss of $7,200,000, higher than the $5,900,000 loss in Q2 2024.
- Cash, Equivalents, and Marketable Securities: $13,400,000 at the end of Q2 2025.

[Q&A Highlights]
Question 1: Could you repeat the expected timeline for clinical trials and 510(k) applications for the Kodiak PCR tests?
Answer: Clinical trials for COVID-19, multiplex flu A/B/COVID-19/RSV, tuberculosis, and HPV tests are expected to begin in 2025. The COVID-19 test will start first, followed by the multiplex flu A/B/RSV test, tuberculosis test, and HPV test. FDA submissions will follow the completion of these trials.

Question 2: Will you prioritize the 510(k) applications in the same order as the clinical trials?
Answer: Yes, the COVID-19 test will be prioritized first, followed by the multiplex flu A/B/RSV test. There is a solid need for all four panels, with COVID-19 still having a vibrant market.

Question 3: What is the expected timeline for commercial launch and marketing strategy?
Answer: Commercialization is expected by mid-2026, following FDA clearance. The marketing strategy will target physician offices, clinics, skilled nursing facilities, home use, and pharmacies in the U.S., and primary health care centers in India.

[Sentiment Analysis]
The tone of the management was cautiously optimistic, emphasizing operational efficiency and strategic focus on the Kodiak PCR platform. Analysts' questions focused on timelines and commercialization strategies, indicating a keen interest in the company's future plans.

[Quarterly Comparison]
| Metric | Q2 2025 | Q2 2024 |
|---------------------------------|-----------------|-----------------|
| Total Revenue | $200,000 | $2,700,000 |
| Total Operating Expenses | $8,200,000 | $10,100,000 |
| Research and Development Expenses| $4,700,000 | $5,600,000 |
| Net Loss | $7,700,000 | $7,600,000 |
| Adjusted EBITDA | -$7,200,000 | -$5,900,000 |
| Cash, Equivalents, and Securities| $13,400,000 | N/A |

[Risks and Concerns]
- Dependence on FDA clearance for commercialization.
- Potential delays in clinical trials and regulatory submissions.
- Financial sustainability amidst ongoing losses and reliance on additional funding.

[Final Takeaway]
Co-Diagnostics is focused on advancing its Kodiak PCR platform through clinical trials and regulatory submissions, with an eye on commercialization by mid-2026. Despite a significant revenue decline, the company is managing expenses and seeking additional funding to support its strategic initiatives. Investors should monitor the progress of clinical evaluations and FDA submissions, as these will be critical to the company's future success.